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Each year, through population-based newborn screening (NBS), 1 in 294 newborns is
identiﬁed with a condition leading to early treatment and, in some cases, life-saving
interventions. Rapid advancements in genomic technologies to screen, diagnose, and
treat newborns promise to signiﬁcantly expand the number of diseases and individuals
impacted by NBS. However, expansion of NBS occurs slowly in the United States (US) and
almost always occurs condition by condition and state by state with the goal of screening for
all conditions on a federally recommended uniform panel. The Newborn Screening
Translational Research Network (NBSTRN) conducted the NBS Expansion Study to
describe current practices, identify expansion challenges, outline areas for improvement
in NBS, and suggest how models could be used to evaluate changes and improvements.
The NBS Expansion Study included a workshop of experts, a survey of clinicians, an analysis
of data from online repositories of state NBS programs, reports and publications of
completed pilots, federal committee reports, and proceedings, and the development of
models to address the study ﬁndings. This manuscript (Part One) reports on the design,
execution, and results of the NBS Expansion Study. The Study found that the capacity to
expand NBS is variable across the US and that nationwide adoption of a new condition
averages 9.5 years. Four factors that delay and/or complicate NBS expansion were
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identiﬁed. A companion paper (Part Two) presents a use case for each of the four factors and
highlights how modeling could address these challenges to NBS expansion.
Keywords: research, genomics, ACMG, NBSTRN, newborn screening

1 INTRODUCTION

treatment early in life thapreventsed or signiﬁcantly reduces
morbidity and mortality (Watson et al., 2006). Treatment
regimens have now evolved to include gene therapy, stem cell
transplant, cochlear implants, surgical repair of congenital heart
defects, enzyme replacement, and genotype-speciﬁc therapies,
(Puck, 2019; De Vivo et al., 2019; Dabbous et al., 2019), leading to
many more conditions for which there may be early, effective
treatment. Moreover, even the tenet of early treatment is being
challenged by the expansions of NBS panels to include conditions
with later childhood and adult-onset forms.
As outlined in the Newborn Screening Saves Lives
Reauthorization Act of 2014 (NBSSLA) (Senate of the
United States, 2019), three federal agencies each play a key
role in advancing and maintaining NBS. 1) The NICHD is
charged with supporting NBS research, including funding and
administering the Newborn Screening Translational Research
Network (Newborn Screening Translational Research Network,
2011), as well as investigator-driven NBS research to discover
novel screening, diagnostic, and treatment technologies, nd NBS
research and implementation pilots. 2) The Health Resources and
Services Administration (HRSA) is tasked with ensuring the
availability of services and providers to care offorBS-screened
patients, administering the Advisory Committee on Heritable
Disorders in Newborns and Children (Advisory Committee on
Heritable Disorders in Newborns and Children, 2016a), funding
NewSTEPs and supporting state adoption pilots. 3) The CDC
operates the Newborn Screening Quality Assurance Program
(NSQAP), a national program that provides training and
assesses the performance of state laboratories conducting
screening (Centers for Disease Control and Prevention, 2020
NSQAP).
Conditions are considered candidates for NBS based on the
RUSP nomination criteria, which includes an assessment of
whether early identiﬁcation and intervention results in
improved health outcomes. Figure 1 describes the different
stages of NBS expansion from research pilots to nationwide
implementation. As shown in the ﬁgure, an important step in
understanding whether a condition is a candidate for NBS is to
conduct research pilots of the entire screening process, including
the screening test, diagnostic testing, clinical referral, and
treatment, to assess the feasibility and potential beneﬁts of
early identiﬁcation and intervention. Prospective or
retrospective studies designed to assess the analytical and
clinical validity of screening methods are often undertaken as
an initial step. These studies or research pilots are typically a
collaboration of multiple state NBS programs, working alone or
with researchers, clinicians, and/or industry (diagnostics, medical
device, and/or drugs), and they capture the initial performance of
the screening test (Elliott et al., 2016). The second step is the
implementation pilot. The NBSSLA authorized the Hunter Kelly
Newborn Screening Research Program to conduct

Each year in the United States (US), at least 12,905 (Sontag et al.,
2020) infants are identiﬁed with a genetic disease through the
multi-component, multi-stakeholder system of newborn
screening (NBS). NBS is recognized as one of the most
successful public health programs in the US (Centers for
Disease Control: Morbidity and Mortality Weekly Report
(MMWR)) because it provides the opportunity to identify atrisk infants in a population regardless of race, income, or location
of birth. Early identiﬁcation of these at-risk infants facilitates
timely diagnosis and administration of often life-saving
treatment.
NBS began in the 1960s when a longitudinal study funded by
the Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD) discovered that newborns
who were identiﬁed as having phenylketonuria (PKU) on a
screening test using a blood spot on ﬁlter paper taken shortly
after birth beneﬁted from early diagnosis and treatment
(Alexander, 2003). This discovery led to newborn screening
pilots for PKU in several states and eventual nationwide
screening of essentially all newborns using state-based public
health laboratories.
Over the past 60 years, the number of possible screened
conditions has increased from 1 to 81, with 75% (61/81) of
these conditions recommended for screening by a federal
advisory committee (Advisory Committee on Heritable
Disorders in Newborns and Children (Advisory Committee on
Heritable Disorders in Newborns and Children, 2010)
Recommended Uniform Screening Panel (RUSP) (Advisory
Committee on Heritable Disorders in Newborns and Children,
2011 RUSP)). Sixty-one conditions are included in the RUSP, and
an additional 20 conditions are screened in at least one state as
reported to the Association of Public Health Laboratories
(Association of Public Health Laboratories Newborn
Screening, 2020) Newborn Screening Technical assistance and
Evaluation Program (NewSTEPs). This increase is largely due to
advances in screening methodologie,s including the development
of tandem mass spectrometry (MS/MS) in particular. The
feasibility of screening for more than one condition using a
single technology platform dramatically increased the number
of conditions amenable to NBS (Ombrone et al., 2016; Farrell
et al., 2020; Martin et al., 2020). In the future, the addition of
genomic technologies to NBS would similarly increase the
number of conditions that are candidates for NBS.
The composition of NBS panels and screening
recommendations have been based on Wilson and Jungner’s
criteria as outlined in “Principles and practice of mass
screening for disease” (Wilson and Jungner, 1968). In
addition, consideration for adding a condition to NBS panels
has historically required onset in the neonatal period and effective
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FIGURE 1 | Pathway of candidate conditions.

implementation pilot studies on conditions recommended by the
(Advisory Committee on Heritable Disorders in Newborns and
Children, 2016b) ACHDNC to ‘‘. . .ensure that screenings are
ready for nationwide implementation.’’
In response, in 2016, NICHD created a pool of three states to
conduct NBS pilots to facilitate the implementation of conditions
recently recommended to the RUSP by the Health and Human
Services (HHS) Secretary, and utilizing the coordinating
infrastructure of the NBSTRN (Puryear et al., 2019). NBSTRN
is a resource for investigators engaged in NBS-related research,
led by the American College of Medical Genetics and Genomics
(ACMG) and funded by a contract from NICHD. While these
implementation pilots generate valuable information and data to
accelerate and support the adoption of screening by state NBS
programs, each state usually conducts state adoption pilots to
demonstrate that they can meet the analytical standards
established during the research and/or implementation pilots
(Hall et al., 2020). Research pilots differ from implementation
pilots, both of which differ from state adoption pilots (Vogel et al.,
2015). However, all three types of pilots focus on the analytical
validity of screening and diagnostic methods. All kinds of pilots
are supported and funded through different mechanisms.
Research pilots are supported by various stakeholders,
including the Centers for Disease Control and Prevention
(Centers for Disease Control and Prevention, 2011), the
National Institutes of Health (NIH, usually NICHD), industry,
and advocacy groups. Implementation pilots are funded by
NICHD and utilize a task order for each pilot available to a
pool of three states, currently New York, Georgia, and North
Carolina. State adoption pilots are funded by the Health
Resources and Services Administration (HRSA) and CDC and
include the acquisition of equipment and training of staff.
Enrollment in prospective research and implementation pilots
occurs in birthing facilities and may require informed consent
from parents. Prospective state adoption pilots are typically

Frontiers in Genetics | www.frontiersin.org

conducted as a component of program improvement and
utilize either archived or routinely collected specimens.
Over the past decade, the NBSTRN coordinated pilot studies
and worked with several researchers and disease advocacy
organizations to compile data and review the scientiﬁc
literature to facilitate the nomination of conditions to the
ACHDNC in addition to the RUSP. To check current
practices, identify expansion challenges, and propose strategies
to evaluate changes and improvements to NBS expansion,
NBSTRN designed and conducted the NBS Expansion Study.
The study included an in-person workshop, a review of state
Practices, completed Pilots, and efforts of the ACHDNC, and an
expert opinion survey on the readiness of candidate conditions
for NBS pilot studies.

2 MATERIALS AND METHODS
2.1 NBS Expansion Study Workshop
Eighteen individuals participated in a 2 day workshop organized
and hosted by NBSTRN staff. Attendees were selected based on
their content knowledge of NBS, technology development and
research, and involvement in NBS programs and pilots.
Overviews of research, implementation, and state adoption
pilots and expansion efforts were given by individuals from
the NICHD pilot states, state NBS programs, and the HRSAfunded APHL NewSTEPs. The conference was recorded and
transcribed. NBSTRN staff analyzed the transcripts and
developed themes. These were presented to attendees for
review, editing, and synthesis into a ﬁnal report that was
submitted to NICHD for consideration. The NBSTRN Steering
Committee, a twelve-person group that guides NBSTRN
activities, reviewed the workshop ﬁndings along with NICHD
feedback and recommended NBSTRN survey state programs to
assess their activities in the longitudinal follow-up of newborns
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conﬁrmed with a diagnosis and conduct an expert opinion survey
to compile and rank the growing pipeline of conditions that are
candidates for NBS pilots and eventual RUSP nomination.

of a single test for a single disease to the identiﬁcation of
numerous disease risks. Metabolomics, proteomics, and otheromics are expected to further complicate this assessment. The
third concept relates to the availability of treatments and
interventions. The modality, urgency, efﬁcacy, effectiveness,
and availability of proposed therapies are important
components in considering a condition for NBS.
Subject matter experts from the NBSTRN expert workgroups
who did not attend the workshop contributed to the survey’s
design. The survey (Supplementary Table S1) administered via
REDCap was distributed to 633 individuals, including
595 medical geneticists, metabolic disease experts, and
laboratorians via the Society for Inherited Metabolic Disease
(SIMD) email list and 38 NBSTRN users and researchers who
conduct NBS pilots. The survey was open for 8 weeks, and two
reminders to complete the survey were sent at weeks three and
six. Likert scale responses were extracted from the survey, and the
mean score for each criterion across respondents was computed.
No opinion ratings were recorded as “0’’ and were excluded from
mean score calculations. Based on consensus and review of the
survey data from NBSTRN Steering Committee members, mean
scores above or equal to 3.5, corresponding to the 70th percentile,
were interpreted as a “yes” for the criteria (“Yes, this condition
has a screening test,” “Yes this condition is severe/urgent,” “Yes
this condition has a treatment”). Mean scores below the 70th
percentile were interpreted as a “no” for the criteria (“No, this
condition does not have a treatment”). Standard errors for each
mean were calculated, and conditions were organized into groups
based on the 70th percentile cut-off. A condition was deemed
ready for pilot testing for NBS inclusion if the mean score for all
three criteria (test, condition, and treatment) was ≥70%.

2.2 Review of NBS and Expansion Efforts to
Date
The online resources, including the NewSTEPs and NBSTRN
online repositories, were reviewed to gather information and data
describing state screening panels and practices. State NBS
program websites were searched to identify legislation that
mandates screening for non-RUSP conditions and identify
results of long-term follow-up of screen-positive cases.
Publications and/or summary reports provided by pilot sites
were reviewed to analyze the number of sites; screened,
referred, and diagnosed newborns; and pilot duration for
Severe Combined Immune Deﬁciency (SCID), Pompe Disease,
Mucopolysaccharidosis Type I (MPS I), and/or X-Linked
Adrenoleukodystrophy (X-ALD). The ACHDNC website,
meeting transcripts, reports, and letters were reviewed to
summarize information related to nominated conditions.

2.3 Expert Opinion Survey on Readiness of
Candidate Conditions for NBS Pilot Studies
NBSTRN staff compiled a list of 46 candidate conditions and
developed a questionnaire that provided the name of the
condition, RUSP status (included, nominated), and listed
informative biomarkers, analytical method, second-tier test,
and available treatment(s). A ﬁve-point Likert scale ranging
from “No” (1) to “Yes” (5) was used to rate each condition for
three criteria that are key to an ACHDNC nomination: 1)
Understanding of the Condition (severity/urgency); 2) Test
Efﬁcacy; and 3) Treatment Efﬁcacy. Criteria could be ranked
as “0’’ when the respondent had “no opinion” about the
condition/criteria (Supplementary Tables S1, S2).
The ﬁrst criteria relate to whether there is sufﬁcient
understanding of the condition in question. This is especially
important because NBS expansion has revealed considerable
clinical variability and incidence differences compared to
predictions from the evidence review. With implementation,
the clinical variability inherent in nearly all screened
conditions becomes evident, uncovering in some cases
variability that is striking.
The second criteria address the availability of a highthroughput, sensitive, and speciﬁc screening algorithm,
including 1st and 2nd tier tests, performed either on dried
blood spots (DBS) or via physiologic assessment at the
bedside. While the ability of MS/MS to screen for multiple
inborn errors of metabolism (IEMs) simultaneously on a
single sample facilitated rapid NBS expansion since the early
2000s, it also further complicated screening because conditions
that did not meet the evidence threshold for inclusion in NBS
could be detected while screening for those conditions that did
meet the evidence. Similarly, genome or exome sequencing has
the potential to identify multiple disease-associated pathogenic
gene variants in a single assay and redeﬁnes assessment from that
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3 RESULTS
The NBS Expansion Study utilized a workshop of NBS experts, a
survey of clinicians, a literature review, and a review of online
resources and key efforts (e.g., ACHDNC, HRSA, CDC, and
NICHD activities) to understand NBS expansion in the US. The
ﬁndings are summarized below and organized by topic and data
source.

3.1 Literature, Online Resources, and Key
Effort Review Findings
3.1.1 NBS Expansion in the United States
In the US, 53 state-and territory-based programs conduct NBS.
Before 2002, the number of screened conditions varied
considerably from state to state ranging between 3 and
43 conditions. To address these differences, in 2002, the
ACMG led a multi-year effort to survey experts and review
the medical literature to assess the availability and
characteristics of screening tests, the availability and
complexity of diagnostic services, and the availability and
efﬁcacy of treatments for 84 conditions considered candidates
for NBS. In 2005, this effort led to the original RUSP, with 29 core
and 25 secondary conditions (Watson et al., 2006). After 3 years,
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TABLE 1 | NBS conditions screened in at least one state but not on RUSP.
Carbamoyl phosphate synthase
(CPS) deﬁciency
Congenital cytomegalovirus infection
Congenital human immunodeﬁciency
virus infection
Congenital toxoplasmosis infection
Ethylmalonic encephalopathy

Fabry disease

Hyperornithinemia with gyrate deﬁciency

Nonketotic hyperglycinemia

Formiminoglutamic acidemia

Hyperornithinemiahyperammonemiahomocitrullinemia syndrome
Krabbe Disease

Ornithine transcarbamylase
(OTC) deﬁciency
Prolinemia Type I/Type II

Mucopolysaccharidosis Type II
Niemann Pick disease

Pyroglutamic acidemia
Zellweger syndrome

GAMT deﬁciency
Gaucher disease
Glucose-6-phosphate
dehydrogenase deﬁciency

all but one NBS program reported screening for all core
conditions. This move to uniformity was achieved in a short
timeframe because 80% (23/29) of the core conditions could be
screened using a common multiplex technology, tandem mass
spectrometry (MS/MS).
Using the ACMG effort as a model, the ACHDNC developed a
nomination and evidence review system that is open to all
stakeholders (Green et al., 2007). Since 2007, 13 conditions
have been nominated and reviewed, and six were
recommended for screening by the ACHDNC and, ultimately,
the HHS secretary. Nomination to the RUSP is open to all
stakeholders, and nominated conditions follow a standard
process of consideration, including an evidence review.
Conditions are usually reviewed one by one, and the review
must be completed within 9 months. While the system in place to
amend the RUSP encourages uniformity across the US by
recommending conditions for screening, state programs are
not obligated to follow those recommendations, and each state
decides on the makeup of its state’s screening panel.

advisory committee recommendation, and advocacy (The
Brack Bills, 2016; Justia US Law, 2019; Connecticut General
Assembly, 2020).

3.1.3 NBS Pilots
Pilots of conditions newly recommended to the RUSP are
conducted in conjunction with at least one state-based NBS
program to assess the analytical and clinical validity of the
screening technology. A review of ﬁve of these pilots, shown
in Table 2, found that the average duration of screening (which
can include multiple state programs) was 8.8 months; the number
of newborns screened ranged from 12,065 to 420,000; each pilot
found at least one case; the screening technology and the followup algorithms used by each state varied; there was no
coordination of data analysis or consensus developed by the
participating states; not all states participated in every pilot;
most pilot ﬁndings were either presented at scientiﬁc meetings
or published within 3 years.
There are no standardized requirements or endpoints for NBS
pilot studies, and the choice of outcomes and the development of
robust statistical endpoints may be complicated because NBS
conditions are rare and may have variable penetrance, age of
onset, and severity. The endpoint for enrollment for some pilot
studies is a deﬁned period of time or population size. In contrast,
others end once a single newborn with the targeted condition has
been identiﬁed and the diagnosis conﬁrmed. As a consequence of
the design of both research and implementation pilots coupled
with the rarity of most diseases, an assessment of the treatment
and long-term health outcomes of NBS-identiﬁed individuals is
not feasible. This makes it difﬁcult to assess the utility of screening
with regard to long-term outcomes, which has only occurred, at
best, after population-based screening has been implemented.
Additionally, there are currently no systematic approaches for
assessing the ethical, social, or behavioral impact of screening for
particular conditions on newborns and their families.
The collection of longitudinal health information from
clinicians, educators, and others that care for these individuals
is critical but very challenging given the variety of health care
systems that hold relevant information on outcomes and the nonreimbursed effort currently required by care providers to enter
follow-up data into systems created for long-term follow-up.
Long-term follow-up is deﬁned by each program based on
state policies and legislation but usually involves collecting
health information beyond diagnosis, treatment, and referral
to clinical care. To make the collection of long-term follow-up

3.1.2 Composition of NBS Panels
A review of current state panels in 2021 using online resources
found that screening for up to 20 non-RUSP conditions is
mandated legislatively in 23 states, representing deviations
from the goal of the RUSP, which is uniformity based on
evidence review (Table 1). These 23 states account for the
screening of 54% (2,116,299/3,883,107) of US newborns
(ACHDNC RUSP). Thirty-ﬁve percent (7/20) of the
conditions have been nominated to the RUSP in the past
(ACHDNC RUSP), and 8/20 (40%) are included in a
completed or current pilot (ScreenPlus, 2022). Since our
review, Mucopolysaccharidosis Type II (MPS II) was
recommended to the RUSP in February 2022. The current
status of state NBS panels can be found on the individual state
websites, as well as the NewSTEPs Repository and the NBSTRN
data tool called the NBS Conditions Resource (NBSTRN NBSCR, 2022). The Newborn Screening Conditions Resource (NBSCR) provides a centralized resource of facts and statistics on both
screened and candidate conditions. The NBS-CR is designed to be
an interactive resource for researchers, clinicians, parents, and
families to learn more about these disorders and links to National
Library of Medicine (NLM) resources, including the National
Center for Biotechnology Information (NCBI). The NBS
programs report several reasons for screening for conditions
that are not on the RUSP, including state legislation, state
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TABLE 2 | NBS pilots after HHS endorsement for RUSP.
Condition

RUSP
addition
(month/
Year)

Number
of
sites

Number
of
newborns
screened

Screening
start

Screening
duration
(months)

Number
referred

Number
diagnosed

Publication
date
(mont
h/year)

Link
to publication

SCID

2/2010

4a

167,509
420,000
32,000
34,544

10/2010

8

247
43
8
9

24
1
7
4
8

8/2014

https://pubmed.ncbi.nlm.nih.gov/
32003821/

Pom pe

3/2015

2

59,332

1/2017

5.5

310

4

1/2020

108,862

NA

NA

13

NAb

https://pubmed.ncbi.nlm.nih.gov/
32003821/
NA

MPS I

2/2016

2

59,332
62,734

1/2017
8/2016

5.5
7

17
1
9

11
1
4

1/2020
8/2019

https://pubmed.ncbi.nlm.nih.gov/
32003821/

X- AL D

2/2016

2

51,081
52,301

7/2017
3/2018

5
4

12
1
2

4
8

NA
1/2020

NA
https://pubmed.ncbi.nlm.nih.gov/
32003821/

SMA

7/2018

2

146,749
12,065

2/2019;
10/2018

12
15

23
2

11
1

NA
3/2021

NA
https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC8006221/

a

NY, CA, WI, conducted screening via courier for Louisiana; MA conducted screening via courier for Puerto Rico.
NA, designates not published.

b

assessment of state readiness to the evidence review process. This
assessment enables a better understanding of the capacity of states
to expand screening and the resources required to support
expansion. An assessment of the capacity of the health care
system, including subspecialties, to conﬁrm diagnoses in
screen-positive infants and manage diagnosed infants would
be informative and facilitate state adoption but is not part of
the current process. As the number of conditions that would
beneﬁt from early identiﬁcation and treatment through NBS
increases, workshop participants noted that a failure to
address resources for follow-up and long-term care would
continue to negatively impact NBS as a system.

TABLE 3 | Implementation status of new RUSP conditions (4/21).
Conditiona
SCID
CCHD
Pompe
MPS I
X-ALD
SMA

HHS recommendation to RUSP

Status

Years

2010
2011
2015
2016
2016
2018

100% (53/53)
100% (53/53)
43% (23/53)
39% (21/53)
34% (18/53)
43% (23/53)

10
9
5+
4+
4+
2+

a

SCID, Severe Combined Immunodeﬁciency; CCHD, Critical Congenital Heart Disease;
MPS I, Mucopolysaccharidosis Type I; X-ALD, X-Linked Adrenoleukodystrophy; SMA,
Spinal Muscular Atrophy.

3.2 Expert Opinion Survey

data more streamlined, the NBSTRN developed the Longitudinal
Pediatric Data Resource (LPDR), which includes common data
elements (CDEs) developed by clinical experts and electronic case
report forms for use by state NBS programs, researchers, and
other stakeholders. NBSTRN aggregates the follow-up data in the
LPDR and makes de-identiﬁed summaries publicly available
(NBSTRN SCID).

The survey was delivered electronically to 633 experts via the
SIMD list serve, 55 logged into the survey, and 65% (36/55)
completed the survey (Supplementary Table S1). Forty-six
conditions were scored for three concepts, totaling
138 possible scores for each respondent. The number of
respondents who ranked the three concepts for each condition
varied because the survey allowed a response of “0’’ for “no
opinion,” and this resulted in an average of 27 respondents per
condition with a range of 13–36. Mean scores and standard errors
were calculated for each concept and condition (Supplementary
Table S2). Two conditions, congenital HIV and guanidinoacetate
methyltransferase deﬁciency (GAMT), ranked above 80% (Likert
rank 4) for all three criteria. An additional 13 conditions ranked
equal to or above 70% (Likert ranked 3.5). Using 70% as a cut-off
for each criterion resulted in 15 conditions ranked as ready for
NBS pilots based on condition understanding, available test, and

3.1.4 Length of Time to Implement a New RUSP
Condition
A review of the implementation status from the NewSTEPs Data
Repository (APHL NewSTEPs) found that the time to achieve
screening across all 53 programs for the ﬁrst condition added to
the RUSP, SCID, was 10 years. This multi-year adoption process
has been repeated for the other ﬁve conditions recommended to
the RUSP, as shown in Table 3. The length of time for
implementing a new condition led the ACHDNC to add an
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TABLE 4 | Conditions meeting the 70% threshold across concepts to identify readiness for NBS pilots.
Condition, test and
treatment> 3.5(n = 15)

Condition and test>
3.5(n = 8)

Acute neonatal bilirubin
encephalopathy
AGAT deﬁciency

Duchenne muscular
dystrophy
Fragile X

Arginase deﬁciency
Cbl C, D deﬁciency

MPS IVA
MTHFR deﬁciency

Congenital HIV

NCL2 neuronal ceroid
lipofuscinosis
Niemann Pick A/B disease
MPS IIIA
Smith lemli opitz syndrome

CPT1A Deﬁciency
Fabry
G6PD
GAMT deﬁciency

Condition and treatment>
3.5(n = 8)
BCKDK deﬁciency
Brown vialetto van laere
syndrome
CPS deﬁciency
Familial hypercholesterolemia
NAGS deﬁciency
OTC Deﬁciency
Wilson Disease
Wolman Disease

Cerebrotendinous
xanthomatosis
Chr. 22 Deletion q11.2
Congenital toxoplasmosis
Creatine transporter
deﬁciency
Cytomegalovirus

All concepts <3.5(n = 3)

3-phosphoglycerate DH deﬁciency
Adenine phosphoribosyltransferase
deﬁciency
Pyruvate DH lipoic acid synthetase
deﬁciency

Friedreich Ataxia
Krabbe Disease
Menkes Disease
Metachromatic
Leukodystrophy
Molybdenum cofactor
Deﬁciency
Niemann Pick C Disease
Pyruvate carboxylase
deﬁciency

Gaucher
Hemoglobin H disease
MPS II
MPS VI
MPS VII
Pyridoxine responsive epilepsy

available treatment. Eight conditions lacked a therapy, an
additional eight conditions lacked a screening test,
12 conditions had understanding but lacked treatment and
test, and three conditions were ranked below the cut-off for all
three criteria (Table 4).

RUSP conditions are added to state NBS panels through the
efforts of advocates and legislation. Over one-third of the nonRUSP conditions have been submitted for evidence review to the
ACHDNC, and 40% are part of current or past pilots. Therefore,
state panels may inform the content of future NBS expansions.
Although the CDC and NewSTEPs organize training and
funding to facilitate state adoption, there is no formal
dissemination plan to share data from pilot studies; thus, the
current pilot system fails to capitalize on opportunities to
disseminate ﬁndings from individual state efforts.

4 DISCUSSION
The NBS Expansion Study explored the addition of conditions to
nationwide NBS, surveyed experts to assess the readiness of
conditions for NBS pilots, and described factors that delay and/
or complicate expansion. Although the number of clinical experts
who completed the survey was low, the individuals who completed
the survey are involved in caring for newborns diagnosed with a
condition through NBS. The pool of potential survey respondents
was based on the SIMD list-serve, and the majority of these
individuals may not be involved in NBS efforts. Future surveys
of clinical experts may beneﬁt from a targeted messaging campaign
to encourage involvement.
The Study identiﬁed four factors that delay and/or complicate
NBS expansion.

4.2 The Short Duration of Pilots Limits
Information About Interventions and Health
Outcomes
While pilot sites are usually able to describe the diagnosis and
initial disposition of the referred cases, the short duration of
pilots often limits the description of health outcomes after
treatment. This results in several missed opportunities,
including the ability to: 1) advance understanding of the
genetic disease; 2) connect the screening for a deﬁned
biomarker with improved outcomes; 3) identify gaps in
evidence to be ﬁlled to support the nomination to the
RUSP; 4) plan for the medical system impact of adding a
condition to screening; and 5) document the effectiveness of
early identiﬁcation through NBS.

4.1 Variability in Screening Panels Persists
A review of individual state NBS screening panels found
growing variation in state NBS panels and shows that the
number of conditions screened ranges from a low of 32 core
conditions to a high of 71 core, secondary, and non-RUSP
conditions combined. A total of 81 different conditions are
screened across the US. The makeup of screening panels is
determined by each state’s NBS program, and each program
develops its own screening and follow-up algorithms. Non-
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4.3 Recent RUSP Additions Expand the
Deﬁnition of NBS
While NBS aims to identify infants with conditions that
beneﬁt from the intervention before the onset of symptoms
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and during the newborn period, recent RUSP additions have
variable onset and/or deﬁned late-onset forms manifesting
far beyond the newborn period, if at all (e.g., Pompe,
heterozygous X-ALD). A tool should be developed to
assess the ethical, social, and behavioral impact of NBS
for such disorders on newborns and families to identify
and mitigate any potential harms to maximize the net
beneﬁt of screening prior to the addition of the condition
to the RUSP.

The datasets presented in this study can be found in online
repositories. The names of the repository/repositories and
accession number(s) can be found in the article/
Supplementary Material.
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4.4 The RUSP Nomination and Evidence
Review Process has Capacity Constraints
The number of conditions candidates for NBS pilots and
nationwide screening continues to increase. The approach of
one-by-one nomination, review, implementation, and state
adoption applied to this pipeline of candidates equates to
decades of pilots designed to assess only the analytical part of
the screening and the short-term follow-up aspect of a complex,
multi-component system.
Although NBS has the potential to revolutionize genomic
medicine through the population-based use of genomics to
screen, diagnose and treat individuals with a genetic disease,
current NBS expansion practices limit the realization of this
promise. Findings from the NBS Expansion Study support the
conclusion that the current approach to the expansion of NBS
(i.e., one-by-one nomination, evidence review and HHS
recommendation, implementation pilots, and state adoption)
does not easily accommodate the hundreds of rare genetic
disorders that could potentially beneﬁt from NBS. The four
factors identiﬁed in our study highlight weaknesses and gaps
in the current system. Addressing these challenges will require
innovative solutions so that the NBS system can be modernized
and become responsive to the rapid advances in screening and
diagnostic technologies, the emergence of novel therapies, and the
expectations of the public (or families/advocates). Our
companion paper, “Using Models to Address Challenges in
Newborn Screening Expansion Study Part Two,” builds upon
these ﬁndings, suggests and prioritizes solutions using some case
studies and models, and outlines a potential future course for NBS
in the US.
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